

COPY OF PAPERS ORIGINALLY FILED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Arto Init ∃Faxaminer : 1645

Serial No.

: 09/975,456

Filed Inventors : October 11, 2001 : Michel Lazdunski

: Gerard Lambeau

Emmanuel Valentin

Title :

NOVEL MAMMALIAN

: SECRETED GROUP : IIF PHOSPHOLIPASE

: A₂

22469

PATENT TRADEMARK OFFICE

Docket No.: 1478-R-00

Confirmation No.: 9176

Dated: May 6, 2002

Commissioner for Patents Washington, DC 20231

Sir:

Certificate of Mailing Under 37 CFR 1.8

For

Postcard Response

Copy of Notice to Comply Substitute Sequence Listing

--Computer readable copy and a printed copy of the Sequence Listing Statement to Support Filing and Submission in accordance with 37 C.F.R. §§ 1.821-1.825--

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Commissioner for Patents, Washington, DC 20231, on the date appearing below.

Name of Applicant, Assignee, Applicant's Attorney or Registered Representative:

Schnader Harrison Segal & Lewis Customer No. 022469

By:	102
	Audam
Date:6	MH 202

COPY OF PAPERS DRIGINALLY FILED

THE UNITED STATES PATENT AND TRADEMARK OFFICE

: 1645

09/975,456

Serial No. Filed **Inventors**

Title

October 11, 2001

Michel Lazdunski Gerard Lambeau

Emmanuel Valentin

NOVEL MAMMALIAN

SECRETED GROUP : IIF PHOSPHOLIPASE

 A_2

PATENT TRADEMARK OFFICE

Docket No.: 1478-R-00

Confirmation No.: 9176

Dated: May 6, 2002

RESPONSE

Commissioner for Patents Washington, DC 20231

Sir:

This is in response to the Patent Office communication dated April 19, 2002, and the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures. A copy of the Notice is enclosed.


We submit herewith a substitute computer readable form (CFR) copy of the Sequence Listing, as well as a substitute paper copy of the Sequence Listing.

I hereby certify that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. §§ 1.821-1.825. Also enclosed is a Statement to Support Filing and Submission in accordance with 37 C.F.R. §§ 1.821-1.825.

Respectfully submitted,

T. Daniel Christenbury Reg. No. 31,750

TDC:kb (215) 563-1810







COMMISSIONER FOR PATENTS United States Patent and Trademark Office WASHINGTON, D.C. 20231 www.uspto.gov

APPLICATION NUMBER

FILING/RECEIPT DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

09/975,456

10/11/2001

Michel Lazdunski

1478-R-00

CONFIRMATION NO. 9176 FORMALITIES LETTER

OC000000007918489

22469 SCHNADER HARRISON SEGAL & LEWIS, LLP 1600 MARKET STREET **SUITE 3600** PHILADELPHIA, PA 19103

RECEIVED

APR 2 9 2007

SH&L IP DEPT. Date Mailed: 04/19/2002

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE **DISCLOSURES**

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

• The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d). Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:


- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice \underline{MUST} be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE



SEE BELOW FOR ADDRESS:

http:/www.uspto.gov/web/offices/pac/checker

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail. Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom. Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

- 1. EFS-Bio (http://www.uspto.gov/ebc/efs/downloads/documents.htm, EFS Submission User Manual - ePAVE)
- 2. U.S. Postal Service: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202
- 3. Hand Carry directly to: U.S. Patent and Trademark Office, Technology Center 1600, Reception Area, 7th Floor, Examiner Name, Sequence Information, Crystal Mall One, 1911 South Clark Street, Arlington, VA 22202

U.S. Patent and Trademark Office, Box Sequence, Customer Window, Lobby, Room 1B03, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202

4. Federal Express, United Parcel Service, or other delivery service to: U.S. Patent and Trademark Office, Box Sequence, Room 1B03-Mailroom, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202